CM Hospitalar SA (VVEO3)

Currency in BRL
0.79
-0.03(-3.66%)
Closed·
VVEO3 is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
0.790.85
52 wk Range
0.561.86
Key Statistics
Bid/Ask
0.78 / 0.80
Prev. Close
0.79
Open
0.83
Day's Range
0.79-0.85
52 wk Range
0.56-1.86
Volume
516.5K
Average Volume (3m)
1.97M
1-Year Change
-31.3043%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
VVEO3 Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
1.22
Upside
+54.43%
Members' Sentiments
Bearish
Bullish
ProTips
Trading at a low earnings multiple

CM Hospitalar SA News & Analysis

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Sell
Technical Indicators
Sell
Moving Averages
Sell

Analyst Ratings

0 Buy
3 Hold
2 Sell
Ratings:
5 analysts
Overall Consensus
Sell

Analysts 12-Month Price Target:

Average 1.22
(+54.43% Upside)

CM Hospitalar SA Earnings Call Summary for Q2/2026

  • Viveo posted Q2 2026 adjusted EPS of -$0.24 vs. -$0.19 expected, missing by 29%; revenue of $2.89B fell short of $3.01B forecast by 4%.
  • Adjusted EBITDA rose to BRL 217M, highest since 2023; gross margin expanded 1.5pp YoY, reaching 2027 targets early despite weak pricing.
  • Free cash flow increased 36.6% QoQ; net leverage improved to 3.73x from 3.88x, marking fifth consecutive quarter of deleveraging.
  • Management expects only gradual margin gains ahead from operational efficiency rather than pricing; focus shifts to new operating model over next 2-3 quarters.
  • Leverage could fall to 3.19x with minimal capital raise or below 3.0x in optimistic scenario; debt maturities pushed to 2029, 2033, and 2034.
Last Updated: 2026-08-12, 09:50 a/m
Read Full Transcript

Earnings

Latest Release
Aug 11, 2026
EPS / Forecast
-0.24 / -0.19
Revenue / Forecast
2.91B / 3.01B
EPS Revisions
Last 90 days

VVEO3 Income Statement

Compare VVEO3 to Peers and Sector

Metrics to compare
VVEO3
Peers
Sector
Relationship
P/E Ratio
4.4x11.8x−0.4x
PEG Ratio
0.040.160.00
Price/Book
0.1x1.1x2.6x
Price / LTM Sales
0.0x0.4x3.0x
Upside (Analyst Target)
54.4%41.2%54.5%
Fair Value Upside
Unlock29.3%7.2%Unlock

CM Hospitalar S/A engages in the distribution of hospital materials, medicines, and nutrition products in Brazil. The company offers material products for cardiac, surgical, urinary, diagnosis, sterilization, wound management, hygiene and protection, infusion, clinical nutrition, orthopedic, and respiratory; and medications, such as painkillers, anesthetics, anti-allergy, antibiotics, antiemetics, antifungals, anti-inflammatory, special control, several, and oncology. It also provides materials for respiratory assistance, therapy, anti-inflammatories, anti-tnf, antacid, antiandrogens, antianemics, anti-asthmatics, antibiotics, anticoagulant, anticonvulsant, monoclonal antibody, anti-growth, antidepressants, antidiabetic drug, antidiuretics, antidote, antiemetics and antinauseants, anti-migraine, antiepileptics, antiestrogens, antifibrinolytics, antiflatulents, antifungals, antihemorrhagic drug, antimicrobial, antineoplastics, antiparathyroid, antiparkinsonian, antipsychotics, systemic antipsoriasis, antirheumatic drugs, anti-varicose, antivirals, beta-blockers, carbohydrate, cycloplegic, contraceptives, contrast, special control, corticosteroids, topical debriding agent, diuretics, several, electrolyte, pancreatic enzyme, erythropoietins, uterine stimulant, cardiac stimulators, growth factor, granulocyte colony stimulating factor, gastroprokinetics, systemic hemostatics, heparins, hepatoprotective and lipotropic agents, hormone, adenohypophyseal hormones, growth hormones, immunoglobulins, immunosuppressants, labor induction drugs, proton pump inhibitor, phosphodiesterase and bone resorption inhibitor, platelet aggregation inhibitors, adenosine diphosphate receptor antagonists, proton pump inhibitors, interleukin inhibitors, subtilisin/kexin type 9 proprotein convertase inhibitors, calcium reabsorption inhibitors, materials, medications, nutrition, therapy, orthopedic therapy. CM Hospitalar S/A was incorporated in 2010 and is headquartered in São Paulo, Brazil.

Employees
6000
Market
Brazil

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
12.32M3.90%9.73M
Other Institutional Investors
325.32M96.10%257.00M
Public Companies & Retail Investors
0.000.00%0.00
Total
337.63M100.00%266.73M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Genoma VI Fundo De Investimento Em Participacoes Multiestrategia22.09%69,762,73455,113
Modal Asset Management Ltda.22.09%69,762,73455,113

People Also Watch

3.45
VAMO3
+2.99%
6.21
HAPV3
-2.82%
4.91
GMAT3
-0.41%

FAQ

What Is the CM Hospitalar (VVEO3) Stock Price Today?

The CM Hospitalar stock price today is 0.79 BRL.

What Stock Exchange Does CM Hospitalar Trade On?

CM Hospitalar is listed and trades on the B3 Stock Exchange.

What Is the Stock Symbol for CM Hospitalar?

The stock symbol for CM Hospitalar is "VVEO3."

What Is the CM Hospitalar Market Cap?

As of today, CM Hospitalar market cap is 249.49M BRL.

What Is CM Hospitalar's Earnings Per Share (TTM)?

The CM Hospitalar EPS (TTM) is 0.18.

When Is the Next CM Hospitalar Earnings Date?

CM Hospitalar will release its next earnings report on Nov 10, 2026.

From a Technical Analysis Perspective, Is VVEO3 a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Buy.

How Many Times Has CM Hospitalar Stock Split?

CM Hospitalar has split 0 times.

How Many Employees Does CM Hospitalar Have?

CM Hospitalar has 6000 employees.

What is the current trading status of CM Hospitalar (VVEO3)?

As of Sep 20, 2026, CM Hospitalar (VVEO3) is trading at a price of 0.79 BRL, with a previous close of 0.79 BRL. The stock has fluctuated within a day range of 0.79 BRL to 0.85 BRL, while its 52-week range spans from 0.56 BRL to 1.86 BRL.

What Is CM Hospitalar (VVEO3) Price Target According to Analysts?

The average 12-month price target for CM Hospitalar is 1.22 BRL, with a high estimate of 2 BRL and a low estimate of 0.7 BRL. 0 analysts recommend buying the stock, while 2 suggest selling, leading to an overall rating of Sell. The stock has an +54.43% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.